4CPS-142 Analysis of prescribing and clinical outcomes of vedolizumab treatment in a university care hospital

BACKGROUND: Vedolizumab became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). The Spanish Drug Agency provided a Therapeutic Positioning Report about the clinical recommendation in the use of vedolizumab and its public funds. PURPOSE:...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Sanchez, E, Yañez, D, Carrion, IM, Montero, O, Martin, CB
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 4: Clinical pharmacy services
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535458/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.233
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller